Compare NATR & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NATR | PEPG |
|---|---|---|
| Founded | 1972 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.0M | 207.1M |
| IPO Year | 1995 | 2022 |
| Metric | NATR | PEPG |
|---|---|---|
| Price | $13.07 | $2.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $28.33 | $11.17 |
| AVG Volume (30 Days) | 173.0K | ★ 669.7K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.00 | 25.61 |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $480,144,000.00 | N/A |
| Revenue This Year | $7.76 | N/A |
| Revenue Next Year | $4.82 | N/A |
| P/E Ratio | $28.23 | ★ N/A |
| Revenue Growth | ★ 5.67 | N/A |
| 52 Week Low | $12.97 | $1.31 |
| 52 Week High | $28.14 | $7.80 |
| Indicator | NATR | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 25.40 | 52.31 |
| Support Level | N/A | $1.50 |
| Resistance Level | $21.17 | $3.14 |
| Average True Range (ATR) | 0.38 | 0.22 |
| MACD | 0.16 | -0.06 |
| Stochastic Oscillator | 8.18 | 9.09 |
Natures Sunshine Products Inc is a natural health and wellness company mainly engaged in the manufacturing and direct selling of nutritional and personal care products. The following Companies' product lines include: General health: Assorted health products related to blood sugar, bone health, cellular health, etc. Immune: offer products that support and strengthen the human immune system, Cardiovascular: Ingredients to give the cardiovascular system optimum support. Digestive: regulates intestinal and digestive functions, Personal care: personal care products for external use, and Weight management: to simplify the weight management process by providing healthy meal replacements. Business segment: Asia, Europe, North America, Latin America, and Other. The majority of revenue is from Asia.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.